These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 18784655)

  • 1. Monoclonal antibody pharmacokinetics and pharmacodynamics.
    Wang W; Wang EQ; Balthasar JP
    Clin Pharmacol Ther; 2008 Nov; 84(5):548-58. PubMed ID: 18784655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacokinetics of monoclonal antibodies].
    Keizer RJ; Huitema AD; Damen CW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):683-8. PubMed ID: 17447593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination mechanisms of therapeutic monoclonal antibodies.
    Tabrizi MA; Tseng CM; Roskos LK
    Drug Discov Today; 2006 Jan; 11(1-2):81-8. PubMed ID: 16478695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interaction studies of therapeutic proteins or monoclonal antibodies.
    Mahmood I; Green MD
    J Clin Pharmacol; 2007 Dec; 47(12):1540-54. PubMed ID: 17962422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
    Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessments of antibody biodistribution.
    Glassman PM; Abuqayyas L; Balthasar JP
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S29-38. PubMed ID: 25707961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody pharmacokinetics and pharmacodynamics.
    Lobo ED; Hansen RJ; Balthasar JP
    J Pharm Sci; 2004 Nov; 93(11):2645-68. PubMed ID: 15389672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development.
    Ovacik M; Lin K
    Clin Transl Sci; 2018 Nov; 11(6):540-552. PubMed ID: 29877608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
    Deng R; Jin F; Prabhu S; Iyer S
    Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):141-60. PubMed ID: 22248267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating the pharmacokinetics of therapeutic antibodies.
    Constantinou A; Chen C; Deonarain MP
    Biotechnol Lett; 2010 May; 32(5):609-22. PubMed ID: 20131077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.
    Levêque D; Wisniewski S; Jehl F
    Anticancer Res; 2005; 25(3c):2327-43. PubMed ID: 16080460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
    Finch DK; Sleeman MA; Moisan J; Ferraro F; Botterell S; Campbell J; Cochrane D; Cruwys S; England E; Lane S; Rendall E; Sinha M; Walker C; Rees G; Bowen MA; Schneider A; Liang M; Faggioni R; Fung M; Mallinder PR; Wilkinson T; Kolbeck R; Vaughan T; Lowe DC
    J Mol Biol; 2011 Aug; 411(4):791-807. PubMed ID: 21723291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A primer on pharmacokinetics.
    Quan DJ
    Nephrol Nurs J; 2008; 35(2):213-5. PubMed ID: 18472692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
    Yogaratnam D; Miller MA; Smith BS
    Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.
    Zhao L; Ji P; Li Z; Roy P; Sahajwalla CG
    J Clin Pharmacol; 2013 Mar; 53(3):314-25. PubMed ID: 23426855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
    Mould DR; Sweeney KR
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):84-96. PubMed ID: 17265746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance and limitations of metabolic drug half-life].
    Buclin T; Biollaz J
    Praxis (Bern 1994); 1997 Oct; 86(43):1693-7. PubMed ID: 9432694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.